Earnings season is back on track today as residents across the Northeast recover from Hurricane Sandy's devastating effects. Some major players in the health-care space -- including pharma companies Pfizer (NYSE:PFE)and Vertex (NASDAQ:VRTX)-- were due to report their quarterly earnings yesterday but decided to give investors a rain check. Biotech MannKind (NASDAQ:MNKD), which is completing clinical trials for its diabetes drug Afrezza, and Cell Therapeutics (NASDAQ:CTIC), which is developing a number of oncology drugs, followed suit and will now post their results on Thursday.
Despite the storm and market closures, a number of health-care companies decided to post their earnings as originally scheduled. To keep up with those that have already reported and those that have postponed, here's an updated schedule:
Monday, Oct. 29:
Array Biopharma (ARRY), Kindred Healthcare (KND), Luminex (LMNX), Owens & Minor (OMI), Five Star Quality Care (FVE), Haemonetics (HAE).
Tuesday, Oct. 30:
Astex Pharmaceuticals (ASTX), Charles River Labs (CRL), Cardiovascular Systems (CSII), Community Health Systems (CYH), DaVita (DVA), Epocrates (EPOC), Geron (GERN), MedAssets (MDAS), Parexel International (PRXL), Theravance (THRX), Universal Health Services (UHS), Allergan (AGN), Aveo Pharmaceuticals (AVEO), Cardinal Health (CAH), CorVel (CRVL), Impax Labs (IPXL), Spectranetics (SPNC), Exactech (EXAC), Exact Sciences (EXAS).
Wednesday, Oct. 31:
Medidata Solutions (MDSO), Acorda Therapeutics (ACOR)
Thursday, Nov 1:
Masimo (MASI), Onyx Pharmaceuticals (ONXX), Universal American (UAM), Cell Therapeutics, MannKind (MNKD), Pfizer (PFE), Vertex
Friday, Nov 2:
Dendreon (Nasdaq: DNDN)
Wednesday, Nov. 7:
Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and Masimo. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.